DE

Bodo Melnik

This inventor holds 0 USPTO granted patents, plus 1 CIPO patent.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bodo Melnik. Retrieved from https://idiyas.com/inventor/bodo-melnik

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0

ph-index = 1


Loading Chart...

Title: Bodo Melnik: Innovator in Atopy Prophylaxis

Introduction

Bodo Melnik is a notable inventor based in Germany, recognized for his contributions to the field of atopy prophylaxis. His innovative approach focuses on the prevention of atopy forms in infants through specific dietary agents.

Latest Patents

Bodo Melnik holds a patent titled "Agent For The Prophylaxis Of Atopy And Methods For Preparing And Using Same." This invention provides a method for atopy prophylaxis by supplying gamma-linolenic acid, dihomo-gamma-linolenic acid, and Prostaglandin E1 (PGE1) to infants. The patent emphasizes the importance of these substances in preventing the occurrence of manifest atopy forms. The agents are preferably incorporated into baby food or administered alongside it.

Career Highlights

Throughout his career, Bodo Melnik has focused on developing innovative solutions for health-related issues. His work has contributed significantly to the understanding and prevention of atopy in infants.

Collaborations

Bodo Melnik has collaborated with Gerd Plewig, a fellow professional in the field. Their partnership has likely enhanced the development and application of innovative health solutions.

Conclusion

Bodo Melnik's work in atopy prophylaxis showcases his commitment to improving infant health through innovative dietary solutions. His contributions are significant in the realm of preventive healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…